- Previous Close
103.75 - Open
101.55 - Bid 102.75 x 30000
- Ask 103.25 x 30000
- Day's Range
99.58 - 101.55 - 52 Week Range
92.20 - 119.60 - Volume
17 - Avg. Volume
6 - Market Cap (intraday)
19.996B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
24.33 - EPS (TTM)
4.11 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield 0.89 (0.86%)
- Ex-Dividend Date Mar 31, 2025
- 1y Target Est
--
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
www.zimmerbiomet.comRecent News: ZIM.F
View MorePerformance Overview: ZIM.F
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIM.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIM.F
View MoreValuation Measures
Market Cap
20.75B
Enterprise Value
26.01B
Trailing P/E
25.28
Forward P/E
13.61
PEG Ratio (5yr expected)
1.53
Price/Sales (ttm)
2.97
Price/Book (mrq)
1.79
Enterprise Value/Revenue
3.66
Enterprise Value/EBITDA
12.47
Financial Highlights
Profitability and Income Statement
Profit Margin
11.77%
Return on Assets (ttm)
4.65%
Return on Equity (ttm)
7.25%
Revenue (ttm)
7.68B
Net Income Avi to Common (ttm)
903.8M
Diluted EPS (ttm)
4.11
Balance Sheet and Cash Flow
Total Cash (mrq)
527.1M
Total Debt/Equity (mrq)
53.07%
Levered Free Cash Flow (ttm)
1.06B